483
Wyeth Pharmaceutical Division of Wyeth Holdings LLCFDA 483 - Wyeth Pharmaceutical Division of Wyeth Holdings LLC - November 10, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Wyeth Pharmaceutical Division of Wyeth Holdings LLC in Sanford, NC, from November 6 to November 10, 2023, identified a significant quality control issue. The firm failed to perform a required test on incoming starting material used in the manufacturing of Fidanacogene Elaparvovec. This indicates a potential lapse in ensuring the quality and safety of materials entering the production process.
- Inspection Date
- November 10, 2023
- Product Type
- Biologics
Open in Dashboard
ID · 0ba1c74f-85e2-4a5f-b9df-a2f55c5a93ad